Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR

Ähnliche Einträge

• Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
  von: Ferris, Robert L, et al.
  Veröffentlicht: (2015)
• Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
  von: Kelly, Ronan J, et al.
  Veröffentlicht: (2015)
• Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial
  von: Siu, Lillian L., et al.
  Veröffentlicht: (2018)
• Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
  von: Rizvi, Naiyer, et al.
  Veröffentlicht: (2015)
• Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
  von: Yang, Hui, et al.
  Veröffentlicht: (2018)